[Combined MTX.5-FU.CDGP for the treatment of head and neck cancer].

Gan To Kagaku Ryoho

Dept. of Sensory and Motor Organs, Division of Otolaryngology Head and Neck Surgery, Faculty of Medicine, Tottori University.

Published: May 2003

Combination chemotherapy including 5-fluorouracil (5-FU) and nedaplatin (CDGP) with methotrexate (MTX) and leucovorin (LV) was administered for modulation in patients with head and neck cancer. We treated 19 patients with MTX.5-FU.CDGP consisting of 150 mg/body of MTX on day 1 followed by a 3-day continuous infusion of 5-FU at 3,500 mg/m2 and 17 injections of LV at 15 mg and infusion of CDGP at 100 mg/m2. Six patients had recurrent head and neck cancer, and 13 had newly diagnosed disease. Eleven of the new patients were concurrently treated with radiation therapy. Treatment-associated toxicity was significant, including mucositis and myelosuppression, but acceptable. Sixteen patients were eligible for evaluation of response. The overall complete response rate was 75.0% (12/16). Patients treated with radiotherapy had a 90.0% (9/10) overall complete response rate.

Download full-text PDF

Source

Publication Analysis

Top Keywords

head neck
12
neck cancer
8
complete response
8
response rate
8
patients
6
[combined mtx5-fucdgp
4
mtx5-fucdgp treatment
4
treatment head
4
neck cancer]
4
cancer] combination
4

Similar Publications

Background: Radioactive iodine (RAI) is a common treatment for various thyroid diseases. Previous studies have suggested susceptibility of parathyroid glands to the mutagenic effect of RAI and the development of primary hyperparathyroidism (PHPT). We tested the possible link between prior RAI treatment, disease presentation, and treatment outcomes.

View Article and Find Full Text PDF

T-helper 17 (Th17) cells significantly influence the onset and advancement of malignancies. This study endeavor focused on delineating molecular classifications and developing a prognostic signature grounded in Th17 cell differentiation-related genes (TCDRGs) using machine learning algorithms in head and neck squamous cell carcinoma (HNSCC). A consensus clustering approach was applied to The Cancer Genome Atlas-HNSCC cohort based on TCDRGs, followed by an examination of differential gene expression using the limma package.

View Article and Find Full Text PDF

Purpose: Financial toxicity (FT) has been linked to higher symptom burden and poorer clinical outcomes for patients with cancer. Despite the availability of validated tools to measure FT, a simple screen remains an unmet need. We evaluated item 12 ("My illness has been a financial hardship to my family and me") of the COmprehensive Score for Financial Toxicity (COST) measure as a single-item FT screening measure.

View Article and Find Full Text PDF

Objective: This multicenter, randomized, double-blind, placebo-controlled, crossover trial aimed to evaluate whether prolonged noisy galvanic vestibular stimulation improves body balance in patients with vestibulopathy.

Materials And Methods: This trial was registered in the Japan Pharmaceutical Information Center Clinical Trials Information registry (jRCT1080224083). Subjects were 20- to 85-year-old patients who had been unsteady for more than one year and whose symptoms had persisted despite more than six months of rehabilitation.

View Article and Find Full Text PDF

Objective: What we hear may influence postural control, particularly in people with vestibular hypofunction. Would hearing a moving subway destabilize people similarly to seeing the train move? We investigated how people with unilateral vestibular hypofunction and healthy controls incorporated broadband and real-recorded sounds with visual load for balance in an immersive contextual scene.

Design: Participants stood on foam placed on a force-platform, wore the HTC Vive headset, and observed an immersive subway environment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!